search
Back to results

Comparison of Blood Pressure Control Achieved in Antihypertensive or Generic Drugs in Moderate to Severe Hypertensive Patients (PRINGEN)

Primary Purpose

Hypertension

Status
Completed
Phase
Phase 4
Locations
France
Study Type
Interventional
Intervention
period with drug (trade name) then period with generic
period with generic then period with drug (trade name)
Sponsored by
Centre Hospitalier Universitaire de Saint Etienne
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Hypertension

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • hypertensive patient known and treated taking at least two antihypertensive
  • Anti-hypertension treatment available in generic form
  • Absence of changes in the anti-hypertension treatment during the previous 3 months

Exclusion Criteria:

  • Patients on dialysis
  • Patients with cardiac arrhythmia
  • Patient refusing ambulatory blood pressure

Sites / Locations

  • CH d'ANNONAY
  • CH de FEURS
  • CH de FIRMINY
  • CH du PUY EN VELAY
  • CH de MONTBRISON
  • CH de ROANNE
  • CH de SAINT-CHAMOND
  • CHU de SAINT-ETIENNE

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

period with drug (trade name) then period with generic

period with generic then period with drug (trade name)

Arm Description

Period of 6 weeks.

Period of 6 weeks.

Outcomes

Primary Outcome Measures

Measure of systolic blood pressure
with holter (ambulatory)

Secondary Outcome Measures

number of side effects
number of side effects per patient with a questionnaire

Full Information

First Posted
July 6, 2016
Last Updated
September 23, 2021
Sponsor
Centre Hospitalier Universitaire de Saint Etienne
search

1. Study Identification

Unique Protocol Identification Number
NCT02853045
Brief Title
Comparison of Blood Pressure Control Achieved in Antihypertensive or Generic Drugs in Moderate to Severe Hypertensive Patients
Acronym
PRINGEN
Official Title
Comparison of Blood Pressure Control Achieved in Antihypertensive or Generic Drugs in Moderate to Severe Hypertensive Patients
Study Type
Interventional

2. Study Status

Record Verification Date
September 2021
Overall Recruitment Status
Completed
Study Start Date
June 11, 2015 (Actual)
Primary Completion Date
March 10, 2021 (Actual)
Study Completion Date
March 10, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Centre Hospitalier Universitaire de Saint Etienne

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Despite a large diffusion for generic anti-hypertensive, they are not currently used. Clinical validation studies could be better to convince users and prescribers than pharmacologic validation only. A pragmatic study to evaluate generic anti-hypertensive efficacy is proposed. It takes place in real conditions of care for hypertensive patients, for a manometer control criteria. The aim of the study is to test the hypothesis of non-inferiority for generic anti-hypertensive for blood pressure control.
Detailed Description
List of drugs : ALDACTONE, FLUMACH, SPIROCTAN, SPIRONONE, FLUDEX, INDATEN, LASILIX, TENSTATEN, ALDACTAZINE, PRINACTIZIDE, SPIROCTAZINE, MODURETIC, AVLOCARDYL, HEMIPRALON, STHASIN, BETATOP, TENORMINE, CELECTOL, DETENSIEL, FELSAN, KERLONE, RAGON, RONALOL, LOPRESSOR, SELOKEN, NEBILOX, TEMERIT, NEVEROL, SECTRAL, ACUITEL, KOREC, BRIEM, CIBACENE, COVERSYL, CAPTOLANE, LOPRIL, FOZITEC, ODRIK, GOPTEN, PRINIVIL, ZESTRIL, RENITEC, TEOULA, ZOFENIL, TRIATEC, KENOMON, ADALATE, CHRONOADALATE, AMLOR, BAYPRESS, DELTAZEN, DILRENE, DIACOR, MONO TILDIEM, FLODIL, IPERTEN, ISOPTINE, LERCAN, ZANIDIP, LEDELCARBERDIPE, LENIBERCARDIPE, DIBERLEPIDINE, XILERMIS, APROVEL, CRISARTERS, IFIRMASTA, FLUPPE, ZELMIRB, ATACAND, KENZEN, KARBIS, COZAAR, LOBERASNAT, LOTANBERSAR, MICARDIS, PRITOR, TOLURA, ZANACODAR, DINORTES, MIRPRESOC, NISIS, TAREG, CUENCA, TIFIVAL, VAGRECOR, VAMADRID, HYPERIUM, PHYSIOTENS, BIPRETERAX, PRETERAX, LODOZ, WYTENS, ACUILIX, KORETIC, BRIAZIDE, CIBADREX, CAPTEA, ECAZIDE, CORENITEC, ENALAVIS, ENALURETIC, COTRIATEC, RADOUCHE, FOZIRETIC, PRINZIDE, ZESTORETIC, COAPROVEL, IFIRMACOMBI, COCRISARTERS, COKENZEN, HYTACAND, COANHYVA, COHESAN , COTAREG, NISISCO, FORTZAAR, HYZAAR, MICARDISPLUS, PRITORPLUS, MARESSI, TOLUCOMBI, TENORDATE, BETA ADALATE

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension

7. Study Design

Primary Purpose
Other
Study Phase
Phase 4
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
50 (Actual)

8. Arms, Groups, and Interventions

Arm Title
period with drug (trade name) then period with generic
Arm Type
Experimental
Arm Description
Period of 6 weeks.
Arm Title
period with generic then period with drug (trade name)
Arm Type
Experimental
Arm Description
Period of 6 weeks.
Intervention Type
Drug
Intervention Name(s)
period with drug (trade name) then period with generic
Intervention Description
The list of drugs is detailed in the "study description"
Intervention Type
Drug
Intervention Name(s)
period with generic then period with drug (trade name)
Intervention Description
The list of drugs is detailed in the "study description"
Primary Outcome Measure Information:
Title
Measure of systolic blood pressure
Description
with holter (ambulatory)
Time Frame
for 24 hours
Secondary Outcome Measure Information:
Title
number of side effects
Description
number of side effects per patient with a questionnaire
Time Frame
at 12 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: hypertensive patient known and treated taking at least two antihypertensive Anti-hypertension treatment available in generic form Absence of changes in the anti-hypertension treatment during the previous 3 months Exclusion Criteria: Patients on dialysis Patients with cardiac arrhythmia Patient refusing ambulatory blood pressure
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Christophe MARIAT, MD PhD
Organizational Affiliation
CHU de SAINT-ETIENNE
Official's Role
Principal Investigator
Facility Information:
Facility Name
CH d'ANNONAY
City
Annonay
ZIP/Postal Code
07100
Country
France
Facility Name
CH de FEURS
City
Feurs
ZIP/Postal Code
42110
Country
France
Facility Name
CH de FIRMINY
City
Firminy
ZIP/Postal Code
42700
Country
France
Facility Name
CH du PUY EN VELAY
City
Le Puy En Velay
ZIP/Postal Code
43000
Country
France
Facility Name
CH de MONTBRISON
City
Montbrison
ZIP/Postal Code
42600
Country
France
Facility Name
CH de ROANNE
City
Roanne
ZIP/Postal Code
42300
Country
France
Facility Name
CH de SAINT-CHAMOND
City
Saint-chamond
ZIP/Postal Code
42400
Country
France
Facility Name
CHU de SAINT-ETIENNE
City
Saint-etienne
ZIP/Postal Code
42000
Country
France

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Comparison of Blood Pressure Control Achieved in Antihypertensive or Generic Drugs in Moderate to Severe Hypertensive Patients

We'll reach out to this number within 24 hrs